Fasting plus tyrosine kinase inhibitors in cancer

Aging

Volumn 7, Issue 12, 2015, Pages 1026-1027

  Caffa, Irene ^a   Longo, Valter D ^a   Nencioni, Alessio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

cancer; Fasting; MAPK signaling; Molecularly; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ANTAGONISTS AND INHIBITORS; DIET; DIET RESTRICTION; GENE EXPRESSION REGULATION; HUMAN; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DIET; FASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RADIOTHERAPY;

EID: 84958159579     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100857     Document Type: Editorial

References (7)

1. Gridelli C et al. Clini cal lung cancer. 2014; 15:173-181.
2. Lee C et al. Science Translational Medicine. 2012; 4:124ra127.
3. Safdie F et al. PloS one. 2012; 7:e44603
4. Raffaghello L et al. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:8215-8220.
5. Caffa I et al. Oncotarget. 2015; 6:11820-11832. DOI: 10.18632/oncotarget.3689
6. Brandhorst S et al. Cell Metab. 2015. pii: S1550-4131(15)00224-7.
7. Eichler HG et al. Nature Reviews Drug Discovery. 2010; 9:277-291.